CN107912771A - 一种具有增强免疫功能的石斛组合物及其制备方法 - Google Patents
一种具有增强免疫功能的石斛组合物及其制备方法 Download PDFInfo
- Publication number
- CN107912771A CN107912771A CN201711060468.XA CN201711060468A CN107912771A CN 107912771 A CN107912771 A CN 107912771A CN 201711060468 A CN201711060468 A CN 201711060468A CN 107912771 A CN107912771 A CN 107912771A
- Authority
- CN
- China
- Prior art keywords
- parts
- stem
- composition
- noble dendrobium
- jujube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 240000004638 Dendrobium nobile Species 0.000 title claims abstract description 53
- 230000036737 immune function Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 22
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 21
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 20
- 244000197580 Poria cocos Species 0.000 claims abstract description 20
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 20
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 19
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 14
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 22
- 241001247821 Ziziphus Species 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- 241000026010 Dendrobium candidum Species 0.000 claims description 13
- 244000241872 Lycium chinense Species 0.000 claims description 12
- 235000015468 Lycium chinense Nutrition 0.000 claims description 12
- 239000003595 mist Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 241001523681 Dendrobium Species 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940042126 oral powder Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 230000000242 pagocytic effect Effects 0.000 abstract description 17
- 230000036039 immunity Effects 0.000 abstract description 15
- 238000002474 experimental method Methods 0.000 abstract description 14
- 210000002540 macrophage Anatomy 0.000 abstract description 13
- 210000002966 serum Anatomy 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 210000004698 lymphocyte Anatomy 0.000 abstract description 7
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract description 6
- 239000003228 hemolysin Substances 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 4
- 210000000822 natural killer cell Anatomy 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 23
- 230000006870 function Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000008782 phagocytosis Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003304 gavage Methods 0.000 description 6
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000003024 peritoneal macrophage Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000000955 splenic vein Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Chemical class CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- -1 lignanoid Natural products 0.000 description 1
- 230000003526 lymphopoietic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
本发明公开了一种具有增强免疫功能的石斛组合物及其制备方法。本发明石斛组合物主要由石斛、黄芪、大枣、枸杞、龙眼肉、茯苓、黄精和低聚麦芽糖组成,能发挥中药复方的整体调节优势,能调节机体免疫功能且毒副作用小。实验证实其能促进小鼠淋巴细胞的增殖及转化和巨噬细胞的吞噬能力,能提高血清溶血素水平、碳廓清吞噬指数和NK细胞的活性,具有明显增强免疫功能的作用,长期服用,有益于人体健康。
Description
技术领域
本发明涉及一种具有增强免疫功能的石斛组合物及其制备方法,属于保健食品产品制造领域。
背景技术
免疫力是人体自身的防御机制,是人体识别和消灭外来侵入的任何异物,处理衰老、损伤、死亡、变性的自身细胞以及识别和处理体内突变细胞和病毒感染细胞的能力。人体的免疫力对预防疾病、保持健康具有十分重要的作用,免疫力低下,则容易发生疾病。当代生活生活节奏快,工作压力大,生活作息不规律,人体的免疫力呈现不稳定的状态,需要加强免疫力以提高身体抵抗疾病的能力,常用的方法为饮食调节。
石斛,始载于《神农本草经》,为兰科植物石斛属金钗石斛、铁皮石斛、马鞭石斛及其近似种的新鲜及干燥茎,是一种常用的贵重药材,其味甘、性微寒、归胃、肾经,具有益胃生津、滋阴清热、润肺止咳、明目强身等功效,有“健康软黄金”之称。《本草纲目》中曾记载“石解强肾益精,厚肠胃、补内血不足,平胃气,长肌肉,益智除惊,有轻身延年之功效”。现代药理实验表明,石斛中的主要活性成分为其中所含的大量多糖类物质,如我们所熟悉的石斛多糖,其具有显著的抗氧化、抗肿瘤、调节免疫功能和降血糖等多种生物学活性,是一种对人体健康很有益处的活性多糖。
超微粉碎是近年来国际上发展非常迅速的一项新技术,与一般粉碎相比,颗粒更小,粒径能达到0.1~10μm。中药材经过超微粉碎后,粒度均匀细密,细胞壁破碎,有利于药物有效成分的溶出,使药材有效成分的提取率大大增加。提取石斛有效成分的一般方法为水提,但提取率不高,容易造成资源浪费,用超微粉碎技术能大大提高石斛有效成分的溶出效率,资源能得到最大程度的利用。
我们国家的食疗文化已有几千年的历史,不少传统中药具有增强免疫力的功能,且具有效果明显、作用温和和毒副作用小等优点,将其制成保健食品,长期服用有益于人体健康,有广阔的开发应用市场。
本发明提供的是一种具有增强免疫功能的石斛组合物及其具体的制备方法。
发明内容
本发明的目的在于提供一种具有增强免疫功能的石斛组合物及其制备方法。
本发明采取的技术方案是:
一种具有增强免疫功能的石斛组合物,由以下重量配比的中药原料药制成:铁皮石斛8-12份,黄芪20-30份,大枣15-25份,枸杞子8-12份,龙眼肉10-20份,茯苓10-20份,黄精20-30份,低聚麦芽糖8-12份。
本发明组合物的原料药的重量配比优选为:
铁皮石斛8份,黄芪20份,大枣15份,枸杞子8份,龙眼肉10份,茯苓10份,黄精20份,低聚麦芽糖8份。
本发明组合物的原料药的重量配比优选为:
铁皮石斛10份,黄芪25份,大枣20份,枸杞子10份,龙眼肉15份,茯苓15份,黄精25份,低聚麦芽糖10份。
本发明组合物的原料药的重量配比优选为:
铁皮石斛12份,黄芪30份,大枣25份,枸杞子12份,龙眼肉20份,茯苓20份,黄精30份,低聚麦芽糖12份。
上述石斛组合物的制备方法,主要包括以下步骤:
(1)按比例称取药材,净选;
(2)将所需石斛放入超微粉碎机进行粉碎,收集微粉(过300目),备用;
(3)将黄芪、大枣、枸杞、龙眼肉、茯苓和黄精放入中药粉碎机进行粗粉碎,收集粗粉,备用;
(4)将粗粉放入中药提取器中,加入8-10倍量的水,加热,连续回流煎煮提取,过滤,收集滤液,减压浓缩成稠浸膏,干燥,粉碎,收集细粉,备用;
(5)将步骤(2)所得微粉、步骤(4)所得细粉与低聚麦芽糖混合均匀,即得。
其中,本发明组合物所述的石斛为金钗石斛、铁皮石斛、马鞭石斛、霍山石斛、紫皮石斛中的一种、两种或多种。
其中,本发明所述的石斛组合物的剂型为口服粉末、片剂、胶囊剂或颗粒剂。
黄芪为多年生草本植物黄芪和内蒙黄芪的根,性微温,味甘,归脾、肺经,有补气升阳,益卫固表,托毒生肌,利水退肿之功效。现代研究发现其主要有效成分为黄芪皂苷、黄芪多糖、氨基丁酸以及多种微量元素,具有提高免疫功能,抗氧化、保护心脑血管、提高记忆力,抗菌、降血脂和降血糖等药理活性。黄芪对正常机体的抗体生成有明显的促进作用,能促进正常人和肿瘤患者的淋巴细胞转化率,提高机体细胞的免疫功能。
大枣为鼠李科枣属植物枣的果实,在《神农本草经》列为上品,历代诸多本草皆有阐述,其味甘平,性温,归心、脾、胃经,具补中益气,养血安神之功。其药理活性广泛,具有调节免疫、抗肿瘤、抗氧化、修复肝损伤和抗疲劳等作用,对造血功能以及肠道运动等也有改善作用。大枣中所含的多糖类成分,具有明显抗补体活性和促进淋巴细胞增殖的作用,它能有效增强有机体免疫力,抑制肿瘤。
枸杞子为茄科植物枸杞或宁夏枸杞的干燥成熟果实,主治肾虚精血不足所致的头晕目眩、耳鸣、神经衰弱、遗精、腰膝酸痛等症。其主要活性成分为枸杞多糖,药理研究表明,枸杞多糖对体液免疫、细胞免疫和红细胞免疫均有促进作用,能促进单核巨噬细胞,NK细胞、树突状细胞的功能发挥,在受体表达、信号传导中起着积极的作用。
龙眼肉为无患子科植物龙眼的假种皮,味甘,性平,无毒;入心、脾二经,不热不寒,和平可贵,具有补益心脾,养血安神的功效。明代李时珍曰:“食品以荔枝为贵,而资益则龙眼为良。”龙眼肉营养丰富,含有丰富的多糖、皂苷、多肽、多酚、氨基酸及微量元素,具有抗氧化、抗衰老、提高免疫力、抗肿瘤、降血糖和促进治理发育等作用。
茯苓为多孔菌科卧菌属真菌的干燥菌核,是一种常用中药,味甘淡,性平,有健脾补中、养心安神、利水渗湿的功能。茯苓中含有化学成分主要有萜类、甾醇类、多糖类和脂肪酸等,现代药理研究表明茯苓具有保肝利尿、降血脂、调节肠道菌群、抗炎、抗肿瘤和增强机体免疫力等多种生物活性。
黄精为百合科植物黄精,多花黄精或滇黄精的干燥根茎,味甘,性平,归脾、肺、肾经,具有健脾、补肾、润肺、生津等功能。化学成分主要为多糖、甾体皂苷、蒽醌类化合物、生物碱、木脂素、维生素和氨基酸等,具有降血糖、降血脂、抗衰老、抗炎、增强免疫力和改善记忆力等作用。其中黄精多糖是增强免疫功能的主要活性成分,实验发现其能增强小鼠的体液和细胞免疫功能,促进骨髓细胞的造血功能。
低聚麦芽糖是采用优质淀粉为原料,通过酶的作用,经过液化、浓缩、干燥等一系列工序精制而成的以低聚异麦芽糖为主要成份的白色粉末状淀粉糖制品。其易消化、甜度低、渗透特性低,不被人体的胃和小肠吸收,但能被双歧杆菌优先利用,促进其繁殖,抑制有害菌的繁殖及有害物质的产生,防止便秘,增强免疫力,降低血脂和胆固醇等方面的功效。
本发明综合利用了石斛、黄芪、大枣、枸杞、龙眼肉和黄精等多种中药原料,并辅以适量的低聚麦芽糖,制成具有增强免疫功能的石斛组合物。这几种药材均具有增强免疫力的功效,几种药材配伍,更发挥中药复方的整体调节作用,使其提高免疫力的功能更强,经实践证明此组合物具有明显的增强免疫功能作用,是一个很好的保健品,长期食用有益于人体健康。
具体实施方式
以下实施例中所使用的原料均购自广州市清平药材市场。
下面结合实施例对本发明作进一步描述:
实施例1
处方:铁皮石斛8份,黄芪20份,大枣15份,枸杞子8份,龙眼肉10份,茯苓10份,黄精20份,低聚麦芽糖8份。
制备方法:
(1)按比例称取药材,净选;
(2)将所需石斛放入超微粉碎机进行粉碎,收集微粉(过300目),备用;
(3)将黄芪、大枣、枸杞、龙眼肉、茯苓和黄精放入中药粉碎机进行粗粉碎,收集粗粉,备用;
(4)将粗粉放入中药提取器中,加入8-10倍量的水,加热,连续回流煎煮提取,过滤,收集滤液,减压浓缩成稠浸膏,干燥,粉碎,收集细粉,备用;
(5)将步骤(2)所得微粉、步骤(4)所得细粉与低聚麦芽糖混合均匀,即得。
实施例2
处方:铁皮石斛10份,黄芪25份,大枣20份,枸杞子10份,龙眼肉15份,茯苓15份,黄精25份,低聚麦芽糖10份。
制备方法:
(1)按比例称取药材,净选;
(2)将所需石斛放入超微粉碎机进行粉碎,收集微粉(过300目),备用;
(3)将黄芪、大枣、枸杞、龙眼肉、茯苓和黄精放入中药粉碎机进行粗粉碎,收集粗粉,备用;
(4)将粗粉放入中药提取器中,加入8-10倍量的水,加热,连续回流煎煮提取,过滤,收集滤液,减压浓缩成稠浸膏,干燥,粉碎,收集细粉,备用;
(5)将步骤(2)所得微粉、步骤(4)所得细粉与低聚麦芽糖混合均匀,即得。
实施例3
处方:铁皮石斛12份,黄芪30份,大枣25份,枸杞子12份,龙眼肉20份,茯苓20份,黄精30份,低聚麦芽糖12份。
制备方法:
(1)按比例称取药材,净选;
(2)将所需石斛放入超微粉碎机进行粉碎,收集微粉(过300目),备用;
(3)将黄芪、大枣、枸杞、龙眼肉、茯苓和黄精放入中药粉碎机进行粗粉碎,收集粗粉,备用;
(4)将粗粉放入中药提取器中,加入8-10倍量的水,加热,连续回流煎煮提取,过滤,收集滤液,减压浓缩成稠浸膏,干燥,粉碎,收集细粉,备用;
(5)将步骤(2)所得微粉、步骤(4)所得细粉与低聚麦芽糖混合均匀,即得。
为了证实本发明石斛组合物具有增强免疫功能的作用,用按实施例1方法制得的组合物,进行了一下动物实验研究:
1实验材料
1.1材料 石斛组合物提取浸膏粉。清洁级昆明种F1代健康雌性小鼠200只,体重为18-22g。
1.2试验设计 小鼠按体重随机分为I、II、III、IV、V,5个试验组,每组40只小鼠(每组再分成4个剂量组,每个剂量组10只小鼠)。其中I组小鼠进行ConA诱导的小鼠脾淋巴细胞转化、NK细胞活性试验;II组小鼠进行耳廓肿胀试验;III组小鼠进行抗体生成细胞检测和半数溶血值(HC50)的测定;IV组小鼠进行小鼠碳廓清试验;V组小鼠进行小鼠腹腔巨噬细胞吞噬鸡红细胞试验。试验动物房温度:22~25℃,相对湿度:55%~70%。
受试样品石斛组合物浸膏人体推荐剂量为12g/(人·d),该试验设低、中、高3个剂量组,分别为1.0、2.0、6.0g/(kg·bw)(分别相当于受试样品人体推荐摄入量的5、10、30倍),另外以无菌水代替受试物作为空白对照组。样品低、中、高剂量配制浓度分别为100、200、600mg/mL,经口每日一次给予小鼠相应剂量的受试物,小鼠灌胃量为0.01mL/(g·bw)。连续灌胃30d后测定各项增强免疫力功能指标。
2实验方法
2.1细胞免疫的功能检测
2.1.1ConA诱导小鼠脾淋巴细胞转化试验 采用MTT法。各剂量组动物连续灌胃30d后,颈椎脱臼法处死小鼠,无菌取脾,置于盛有适量无菌Hank’s液的小平皿中,研磨脾脏,制成单个细胞悬液,经200目筛网过滤,用Hank’s液洗2次,每次1000r/min离心10min,然后将细胞悬浮于RPMI 1640完全培养液中并调整细胞浓度为3×106个/mL(同时用台酚蓝染色计数,保证活细胞数均在95%以上)。将细胞悬液分两孔加入24孔培养板中,每孔1mL,一孔加入75μl ConA液,另一孔作为对照,置37℃、5%CO2培养箱中培养72h。培养结束前4h,每孔轻轻吸去上清液0.7mL,加入0.7mL不含小牛血清的RPMI 1640培养液,同时加入MTT(5mg/mL)50μL/孔,继续培养4h。培养结束后,每孔加入1mL酸性异丙醇,混匀,使紫色结晶完全溶解。将溶解液移入96孔培养板中,每孔做3个平行试验,用酶标仪在570nm波长下测定各样品的吸光度值。用加ConA孔的光密度值减去不加ConA孔的吸光度值(ΔA)代表淋巴细胞的增殖能力。
2.1.2 DNFB诱导小鼠迟发型变态反应(DTH)采用耳肿胀法。各剂量组动物连续灌胃30d后,将每只小鼠腹部毛剃去,范围约3cm×3cm,用10mg/mL DNFB溶液50μl均匀涂抹致敏。5d后用10mg/mL DNFB溶液10μL均匀涂抹于小鼠右耳(两面)进行攻击,攻击后24h颈椎脱臼处死小鼠,剪下左右耳壳,用打孔器取下直径8mm耳片,称重。用左右耳重量之差(Δm)表示DTH的程度。
2.2体液免疫功能检测
2.2.1抗体生成细胞检测 采用Jerne改良玻片法。各剂量组动物连续灌胃30d后,每只鼠腹腔注射2%(V/V)的SRBC悬液0.2mL进行免疫,5d后处死小鼠,无菌取脾,制成细胞浓度为5×106个/mL的脾细胞悬液。将琼脂糖加热溶解后与等量双倍浓度Hank’s液混合,分装小试管,每管0.5mL,再向管内加10%(V/V,用SA液配制)压积SRBC 50mL、脾细胞悬液20μL,迅速混匀后倾倒于以刷琼脂糖薄层的玻片上(2个平行片),待琼脂凝固后将玻片水平扣放在片架上,放入37℃、5%CO2培养箱中1.5h,然后用SA缓冲液稀释的补体(1∶10)加入到玻片架凹槽内,继续温育1.5h,计数溶血空斑数。用空斑数/106脾细胞来表示。
2.2.2血清溶血素测定 采用HC50。各剂量组动物连续灌胃30d后,制备2%(V/V)的SRBC悬液,每只鼠腹腔注射0.2mL进行免疫,4d后摘除眼球取血于离心管内,放置1h,2000r/min离心10min,分离并收集血清。血清稀释200倍后,按检验方法测定样品管及SRBC半数溶血时的光密度值。溶血素的量以HC50表示,受试样品组HC50显著高于对照组的HC50,可判断该项试验结果呈阳性。
2.3单核-巨噬细胞功能检测
2.3.1小鼠碳廓清试验 各剂量组动物连续灌胃30d后,按0.01mL/(g·bw)剂量给小鼠尾静脉注入印度墨汁,立即计时,于注入墨汁后2、10min分别从眼内眦静脉丛取血20μL,并立即将其加入到2ml 0.1%Na2CO3溶液中,用紫外分光光度计在600nm波长处测定光度值(A),以0.1%Na2CO3溶液作空白对照。同时将小鼠处死,取肝脏和脾脏,用滤纸吸干脏器表面血污,分别称重(g)。按下式计算吞噬指数(α)。以α表示小鼠碳廓清的能力。受试样品的吞噬指数显著高于对照组的吞噬指数,则可判定该项试验结果为阳性。
吞噬指数(α)=体重/(肝重+脾重)×k1/3
k=(lgA1-lgA2)/(t2-t1)
式中,α为吞噬指数;k为廓清指数;A1为t1时的吸光度值;A2为t2时的吸光度值;t1为给墨汁后第1次取血的时间;t2为给墨汁后第2次取血的时间。
2.3.2小鼠腹腔巨噬细胞吞噬鸡红细胞试验 采用半体内法。各剂量组动物连续灌胃30d后,制备20%(V/V)的鸡红细胞悬液,每只鼠腹腔注射1mL,间隔30min,颈椎脱臼处死小鼠,腹腔注入2mL生理盐水,吸出腹腔液制片,置37℃孵箱温育30min。取出玻片于生理盐水中漂洗后晾干,用甲醇-丙酮(1∶1,V/V)溶液固定,4%Giemsa-磷酸缓冲液(V/V)染色再用蒸馏水漂洗,油镜下每片计数100个巨噬细胞,观察记录吞噬鸡红细胞的巨噬细胞数及被吞噬的鸡红细胞数,计算吞噬百分率和吞噬指数。
吞噬率(%)=(吞噬鸡红细胞总数的巨噬细胞数)/(计数的巨噬细胞数)×100%
吞噬指数=(被吞噬的鸡红细胞总数)/(计数的巨噬细胞数)
2.3.3 NK细胞活性测定 采用乳酸脱氢酶测定法。各剂量组动物连续灌胃30d后,将小鼠颈椎脱臼处死,无菌取脾,制成脾细胞悬液2×107个/mL,取传代后24h生长良好的YAC-1细胞为靶细胞,取4×105个/mL靶细胞和效应细胞各100μL(效靶比50∶1)加入U型96培养板中;靶细胞自然释放孔加靶细胞和培养液各100μL,靶细胞最大释放孔加靶细胞和2.5%Triton各100μL。上述各项各设3个平行孔,置37℃、5%CO2培养箱中培养4h。然后将96孔培养板以1500r/min离心5min,每孔吸取上清100μl置平底96孔培养板中,同时加入LDH基质液100μL,反应10min,每孔加入1mol/L盐酸30μL,在酶标仪490nm处测定光密度值(OD),计算NK细胞活性。
2.4数据处理 用SPSS18.0软件对各试验数据进行方差齐性检验,对于满足方法要求的数据资料,用单因素分析方法中多个试验组与一个对照组间均数的两两比较方法进行统计处理;对非正态分布或方差不齐的数据资料进行适当的变量转换,待满足正态或方差齐要求后用转换所得数据进行统计处理。
2.5结果判定 在细胞免疫功能(ConA诱导小鼠脾淋巴细胞转化试验、DNFB诱导小鼠迟发型变态反应)、体液免疫功能(抗体生成细胞检测、血清溶血素测定)。单核-巨噬细胞功能(小鼠碳廓清、小鼠腹腔巨噬细胞吞噬鸡红细胞试验)、NK细胞活性4个指标中,任意2个结果为阳性,则可判定该受试样品具有增强免疫力的功能。其中细胞免疫功能、体液免疫功能和单核-巨噬细胞功能测定项目中的2个试验结果均为阳性,或任意1个试验的2个剂量组结果为阳性,则可判定该功能结果为阳性。NK细胞活性测定试验的1个以上剂量组结果为阳性,则可判定该功能结果为阳性。
3实验结果
3.1石斛组合物对小鼠细胞免疫的影响
3.1.1石斛组合物对ConA诱导的小鼠脾淋巴细胞转化的影响。由表1可见,中、高2个剂量组[1.0、3.0g/(kg·bw)]的ΔA值与空白对照组的ΔA值比较差异显著(P<0.05),表明该石斛组合物具有促进小鼠淋巴细胞增殖、转化能力的作用,即可判断该项试验结果呈阳性。
3.1.2石斛组合物对DNFB诱导的小鼠DTH的影响。从表1可见,各剂量组小鼠的左右耳片重量差值均高于阴性对照组,且高剂量组与阴性对照组比较差异显著(P<0.05),表明石斛组合物具有促进小鼠的迟发型变态反应的作用。
3.2石斛组合物对小鼠体液免疫的影响
3.2.1石斛组合物对小鼠抗体生成细胞(溶血空斑数)的影响。从表1可见,中、高剂量组小鼠的溶血空斑数高于空白对照组,且差异显著(P<0.05),表明石斛组合物具有促进小鼠的抗体生成细胞增殖的能力。
3.2.2石斛组合物对小鼠血清HC50的影响。由表1可知,各剂量组小鼠的抗体积数均高于阴性对照组,其中高剂量组与阴性对照组比较差异显著(P<0.05),表明石斛组合物具有提高小鼠的血清溶血素水平的作用。
表1 石斛组合物对小鼠细胞免疫及体液免疫的影响(x±SD)
注:*表示与空白对照组比较P<0.05。
3.3石斛组合物对小鼠单核-巨噬细胞吞噬功能的影响
3.3.1石斛组合物对小鼠碳廓清能力的影响。从表2可见,各剂量组小鼠的吞噬指数均高于空白对照组,且高剂量组与空白对照组比较差异显著(P<0.05),表明石斛组合物具有促进小鼠的单核-巨噬细胞碳廓清功能的作用。
3.3.2石斛组合物对小鼠腹腔巨噬细胞吞噬鸡红细胞能力的影响。表2显示,各剂量组小鼠的腹腔巨噬细胞对鸡红细胞的吞噬率及吞噬指数与空白对照组比较均有明显提高,且高剂量组的吞噬率与空白对照组相比差异显著(P<0.05),表明石斛组合物对小鼠腹腔巨噬细胞的吞噬功能有促进作用。
3.4石斛组合物对小鼠NK细胞活性的影响由表2可见,各剂量组小鼠的NK细胞活性均高于空白对照组,且中、高剂量组与空白对照组比较差异极显著,表明石斛组合物能显著提高小鼠的NK细胞活性。
表2石斛组合物对小鼠单核-巨噬细胞吞噬功能及NK细胞活性的影响(x±SD)
注:*表示与空白对照组比较P<0.05;**表示与空白对照组比较P<0.01。
4实验结论
本实验结果表明,与阴性对照组比较,该石斛组合物的中、高剂量组能促进小鼠的迟发型变态反应、淋巴细胞的增殖及转化、抗体生成细胞的增殖能力和巨噬细胞的吞噬能力,能提高血清溶血素水平、碳廓清吞噬指数和NK细胞的活性,说明该石斛组合物具有明显的增强免疫功能的作用,且作用与剂量有密切的联系。
Claims (8)
1.一种具有增强免疫功能的石斛组合物及其制备方法,其特征在于,由以下重量配比的中药原料药制成:铁皮石斛8-12份,黄芪20-30份,大枣15-25份,枸杞子8-12份,龙眼肉10-20份,茯苓10-20份,黄精20-30份,低聚麦芽糖8-12份。
2.根据权利要求1所述的组合物及其制备方法,其特征在于由下列重量配比的原料药组成:铁皮石斛8份,黄芪20份,大枣15份,枸杞子8份,龙眼肉10份,茯苓10份,黄精20份,低聚麦芽糖8份。
3.根据权利要求1所述的组合物及其制备方法,其特征在于由下列重量配比的原料药组成:铁皮石斛10份,黄芪25份,大枣20份,枸杞子10份,龙眼肉15份,茯苓15份,黄精25份,低聚麦芽糖10份。
4.根据权利要求1所述的组合物及其制备方法,其特征在于由下列重量配比的原料药组成:铁皮石斛12份,黄芪30份,大枣25份,枸杞子12份,龙眼肉20份,茯苓20份,黄精30份,低聚麦芽糖12份。
5.根据权利要求1-4所述的组合物,其特征在于所述的石斛为金钗石斛、铁皮石斛、马鞭石斛、霍山石斛、紫皮石斛中的一种、两种或多种。
6.根据权利要求1-5任一项所述的应用,其特征在于所述石斛组合物由以下步骤组成:
(1)按比例称取药材,净选;
(2)将所需石斛放入超微粉碎机进行粉碎,收集微粉(过300目),备用;
(3)将黄芪、大枣、枸杞、龙眼肉、茯苓和黄精放入中药粉碎机进行粗粉碎,收集粗粉,备用;
(4)将粗粉放入中药提取器中,加入8-10倍量的水,加热,连续回流煎煮提取,过滤,收集滤液,减压浓缩成稠浸膏,干燥,粉碎,收集细粉,备用;
(5)将步骤(2)所得微粉、步骤(4)所得细粉与低聚麦芽糖混合均匀,即得。
7.根据权利要求6所述的组合物,其特征在于:组合物的剂型为口服粉末或制剂。
8.根据权利要求7所述的组合物,其特征在于:口服制剂选自片剂、胶囊剂、颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711060468.XA CN107912771A (zh) | 2017-10-23 | 2017-10-23 | 一种具有增强免疫功能的石斛组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711060468.XA CN107912771A (zh) | 2017-10-23 | 2017-10-23 | 一种具有增强免疫功能的石斛组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107912771A true CN107912771A (zh) | 2018-04-17 |
Family
ID=61895145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711060468.XA Pending CN107912771A (zh) | 2017-10-23 | 2017-10-23 | 一种具有增强免疫功能的石斛组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107912771A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198639A (zh) * | 2018-09-26 | 2019-01-15 | 湖北省医药工业研究院有限公司 | 一种用于增强免疫力的组合物及其制备方法和应用 |
CN113908251A (zh) * | 2021-12-13 | 2022-01-11 | 广东益可维生物技术有限公司 | 提高免疫力的中药组合物、中药发酵酸奶及其制备方法 |
CN114128885A (zh) * | 2021-11-26 | 2022-03-04 | 杭州医学院 | 具有调节免疫、促进肠蠕动和调节肠道菌群作用的石斛复方制剂及其制备方法和应用 |
-
2017
- 2017-10-23 CN CN201711060468.XA patent/CN107912771A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198639A (zh) * | 2018-09-26 | 2019-01-15 | 湖北省医药工业研究院有限公司 | 一种用于增强免疫力的组合物及其制备方法和应用 |
CN114128885A (zh) * | 2021-11-26 | 2022-03-04 | 杭州医学院 | 具有调节免疫、促进肠蠕动和调节肠道菌群作用的石斛复方制剂及其制备方法和应用 |
CN113908251A (zh) * | 2021-12-13 | 2022-01-11 | 广东益可维生物技术有限公司 | 提高免疫力的中药组合物、中药发酵酸奶及其制备方法 |
CN113908251B (zh) * | 2021-12-13 | 2022-03-25 | 广东益可维生物技术有限公司 | 提高免疫力的中药组合物、中药发酵酸奶及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104435749B (zh) | 一种铁皮石斛复方制剂及其制备方法和应用 | |
CN104473171B (zh) | 一种火麻含片及其制备方法 | |
CN104666892A (zh) | 一种用于增强免疫、缓解疲劳的黄精人参配方及其制作方法 | |
CN108926702A (zh) | 一种用于调理亚健康状态的中草药配方及其制备方法 | |
CN106819833A (zh) | 一种降血糖调血脂的面条及其制备方法 | |
CN104147360A (zh) | 一种去除人参燥性的组合物及其制备方法 | |
CN105707598A (zh) | 一种解酒植物饮品及其制备方法 | |
CN107912771A (zh) | 一种具有增强免疫功能的石斛组合物及其制备方法 | |
CN105341893A (zh) | 一种辅助降血糖的组合物及应用 | |
CN104013733B (zh) | 一种防治化学性肝损伤的壳聚糖组合物及其制备方法 | |
CN105935374A (zh) | 全麻素在制备治疗消渴症药物中的应用 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN103155985A (zh) | 一种黄精营养粉及其制备方法 | |
CN103520318B (zh) | 一种增强免疫功能的中药组合物及其制备方法 | |
CN107836619A (zh) | 一种具有增强免疫力和抗疲劳作用的牛大力固体饮料及其制备方法 | |
CN104758331A (zh) | 一种增强免疫力的中药组合物及其制备方法 | |
CN107349332A (zh) | 一种鹿胶口服液及其制备方法 | |
CN106362004A (zh) | 一种复方鲜石斛颗粒及其制备方法 | |
CN108066384A (zh) | 一种具有增强免疫力功能的中药制剂及其制备方法 | |
CN105687480A (zh) | 一种免疫调节的中药组合物及制剂 | |
CN104825821A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN112494569B (zh) | 一种提高免疫力的中药组合物及其制备方法和用途 | |
CN104225425A (zh) | 一种提高免疫力、改善睡眠、预防心脑血管疾病的中药制剂及其制备方法 | |
CN107737280A (zh) | 用于治疗糖尿病的中药组合物及其制备方法和应用 | |
CN104771595B (zh) | 一种增强免疫力的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180417 |
|
WD01 | Invention patent application deemed withdrawn after publication |